Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent
Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent
复制标题
DOI：
10.21873/anticanres.11748
复制
发表时间：
2017-07-01
影响因子：
2
通讯作者：
Tachimori, Yuji
中科院分区：
文献类型：
--
作者：
Honma, Yoshitaka;Hokamura, Nobukazu;Tachimori, Yuji
背景资料：在第七版国际癌症控制联盟（UICC）TNM分类中，胸段食管癌（EC）的锁骨上淋巴结（SCLN）被视为远处器官，因此，如果可切除，SCLN转移被认为是全身化疗的候选者。本研究的目的是阐明以根治性治疗为目的的可切除胸EC伴SCLN转移（M1LYM）患者的生存结局。患者和方法：回顾性分析了食管切除术或确定性放化疗（dCRT）治疗的可切除胸EC伴SCLN转移（M1LYM）患者的临床结局。结果：共102例患者分为3组：手术联合围手术期治疗，n=45;单纯手术，n=19; dCRT，n=38。总体而言，中位无进展生存期和中位生存时间分别为9.3和26.7个月。手术联合围手术期治疗组的中位生存期为27.5个月，单纯手术组为50.6个月，dCRT组为22个月。三组间生存率无显著差异。结论：超过30%的可切除M1LYM患者接受根治性治疗后获得长期生存。
Background: In the seventh edition of the Union for International Cancer Control (UICC) TNM classification, supraclavicular lymph node (SCLN) in regard to thoracic esophageal cancer (EC) is regarded as a distant organ, therefore, if resectable, SCLN metastasis is considered a candidate for systemic chemotherapy. The purpose of this study was to clarify the survival outcome in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated with curative intent. Patients and Methods: Clinical outcomes in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated by esophagectomy or definitive chemoradiotherapy (dCRT) were retrospectively analyzed. Results: A total of 102 patients were divided in three groups: Surgery with perioperative therapy, n=45; surgery alone, n=19; and dCRT, n=38. Overall, median progression-free survival and median survival time were 9.3 and 26.7 months, respectively. The median survival time was 27.5 months in the group treated with surgery with perioperative treatment, 50.6 months in those treated with surgery alone, and 22 months in the dCRT group. No significant survival difference was seen among the three groups. Conclusion: Over 30% of patients with resectable M1LYM treated with curative intent achieved long-term survival.